



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 May 2020
EMA/CVMP/212882/2020
Committee for Medicinal Products for Veterinary Use

CVMP assessment report for an application for the granting of a community marketing authorisation for Prevexxion RN (EMA/V/C/005058/0000)

Introduction	4
Marketing authorisation under exceptional circumstances	4
Scientific advice.....	4
MUMS/limited market status	4
Part 1 - Administrative particulars	5
Detailed description of the pharmacovigilance system	5
Manufacturing authorisations and inspection status.....	5
Overall conclusions on administrative particulars	5
Part 2 – Quality	6
Chemical, pharmaceutical and biological/microbiological information (quality)	6
Qualitative and quantitative particulars of the constituents	6
Qualitative and quantitative particulars	6
Container and closure	7
Product development	8
Description of the manufacturing method	10
Production and control of starting materials	11
Starting materials listed in pharmacopoeias	11
Specific materials not listed in a pharmacopoeia	12
Starting materials of biological origin	12
Starting materials of non-biological origin	13
In-house preparation of media and solutions consisting of several components	13
Control tests during the manufacturing process	13
Control tests on the finished product	14
Batch-to-batch consistency	15
Stability.....	15
Overall conclusions on quality	16
Part 3 – Safety	16
Introduction and general requirements.....	16
Safety documentation	17
Laboratory tests	18
Safety of one administration of one dose and of an overdose	18
Safety of the repeated administration of one dose	19
Examination of reproductive performance	19
Examination of immunological functions	19
Special requirements for live vaccines	20
Dissemination in the vaccinated animal	20
Spread of the vaccine strain.....	21
Reversion to virulence of attenuated vaccines	21
Biological properties of the vaccine strain – Residual pathogenicity	22
Biological properties of the vaccine strains – Replication particularities	23
Safety for various species	23
Recombination or genomic reassortment of the strains.....	24
User safety	24
Study of residues.....	25
Interactions	25

Field studies.....	25
Environmental risk assessment	27
Environmental risk assessment for products containing or consisting of genetically modified organisms.....	27
Overall conclusions on the safety documentation	27
Part 4 – Efficacy	29
Introduction and general requirements.....	29
Challenge model:	29
Efficacy parameters and tests:	29
Efficacy documentation	29
Laboratory trials	31
Dose determination.....	31
Onset of immunity	31
Duration of immunity	32
Maternally derived antibodies (MDA)	32
Interactions	32
Overall conclusion on efficacy.....	36
Part 5 – Benefit-risk assessment	36
Introduction.....	36
Benefit assessment.....	37
Direct therapeutic benefit	37
Additional benefits	37
Risk assessment	37
Risk management or mitigation measures	38
Evaluation of the benefit-risk balance.....	38
Conclusion on benefit-risk balance	38

Introduction

The applicant Boehringer Ingelheim Vetmedica GmbH (formerly Merial) submitted on 29 November 2018 an application for a marketing authorisation to the European Medicines Agency (the Agency) for Prevexxion RN, through the centralised procedure under Article 3(1) of Regulation (EC) No 726/2004 (mandatory scope).

The eligibility to the centralised procedure was agreed upon by the CVMP on 25 May 2018 as Prevexxion RN has been developed by recombinant DNA technology.

The applicant applied for the following indications:

For active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by Marek's disease (MD) virus (including very virulent MD virus).

The active substance of Prevexxion RN is a live recombinant avian herpesvirus (Marek's disease virus), genetically modified to contain genomic parts of three different serotype 1 MD virus strains. The target species is chickens. The product is intended for administration by subcutaneous (SC) route.

Prevexxion RN consists of a frozen viral suspension (concentrate) to be diluted in an aqueous solvent to obtain the final suspension for injection. Each dose of vaccine (0.2 ml) contains 2.9 to 3.9 log₁₀ plaque forming units (PFU) of live recombinant Marek's disease virus, serotype 1, strain RN1250.

The vaccine is presented in glass ampoules containing 1,000, 2,000 or 4,000 doses in packs sizes of 5 ampoules per carrier (1,000-dose and 2,000-dose presentations) or 4 ampoules per carrier (4,000-dose presentation). The solvent is presented in plastic bags containing 200 ml, 400 ml, 600 ml, 800 ml, 1,000 ml, 1,200 ml, 1,600 ml, 1,800 ml or 2,400 ml.

The rapporteur appointed is Frédéric Klein and the co-rapporteur is Esther Werner.

The dossier has been submitted in line with the requirements for submissions under Article 12(3) of Directive 2001/82/EC – full application.

Marketing authorisation under exceptional circumstances

Not applicable.

Scientific advice

Not applicable.

MUMS/limited market status

Not applicable.

Part 1 - Administrative particulars

Detailed description of the pharmacovigilance system

A detailed description of the pharmacovigilance system (DDPS V8.1 (version 3), dated September 2017) which fulfils the requirements of Directive 2001/82/EC was provided. Based on the information provided the applicant has the services of a qualified person responsible for pharmacovigilance and the necessary means for the notification of any adverse reaction occurring either in the Community or in a third country. There are no outstanding issues.

Manufacturing authorisations and inspection status

Manufacturer of the active substance

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint Priest
FRANCE

Manufacturer of the solvent

Laboratoire BIOLUZ
Zone Industrielle de JALDAY
64500 SAINT JEAN DE LUZ
FRANCE

Manufacturer responsible for batch release

Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint Priest
FRANCE

General comments on compliance with GMP, GLP, GCP:

All manufacturing sites have been recently inspected by the French competent authorities and were found to be GMP compliant with regard to the applicable manufacturing activities. GMP certificates are available in EudraGMP database.

Overall conclusions on administrative particulars

The detailed description of the pharmacovigilance system was considered in line with legal requirements.

The GMP status of the active substance(s) and of the finished product manufacturing sites has been satisfactorily established and is in line with legal requirements.

Part 2 – Quality

Chemical, pharmaceutical and biological/microbiological information (quality)

Qualitative and quantitative particulars of the constituents

Qualitative and quantitative particulars

Prevexxion RN vaccine consists of a frozen cell-associated viral suspension containing one active ingredient, a live recombinant Marek's disease virus serotype 1 (RN1250 component), to be diluted in an aqueous solvent used for the suspension preparation of Boehringer Ingelheim Vetmedica GmbH (formerly Merial) frozen vaccines against Marek's disease. The solvent does not contain any active ingredient.

The composition of the frozen cell-associated cell suspension and solvent is present in the tables below.

Frozen cell suspension:

	Names of ingredients	Quantity per dose	Function	References
Active ingredient	RN1250 component	$10^{2.9} \leq R \leq 10^{3.9}$ PFU	Supply of antigen	MERIAL
Constituents of the adjuvant	NA	NA	NA	NA
Constituents of the excipients	Dimethyl sulfoxide Dilution medium <i>Composition for 1 ml:</i> . 199 Earle Medium . Sodium hydrogen carbonate . Hydrochloric acid . Water for injections	0.0375-0.075 µl* q.s. one dose 9.6 mg 2.35 mg q.s. pH q.s. 1 ml	Freezing excipient	Ph.Eur. MERIAL MERIAL Ph. Eur. MERIAL Ph. Eur.
Constituents of the solvent	NA	NA	NA	NA
Constituents of the pharmaceutical form	NA	NA	NA	NA

NA: Not applicable, Ph. Eur.: European Pharmacopoeia; PFU: Plaque forming units

* According to the presentation (1000, 2000 or 4000 doses).

Solvent for dilution:

	Names of ingredients	Quantity per l	Function	References
Active ingredients	NA	NA	NA	NA
Constituents of the adjuvant	NA	NA	NA	NA
Constituents of the excipient	NA	NA	NA	NA
	Sucrose	51.25 g	Nutritive component and osmolarity agent	Ph.Eur.
	Casein hydrolysate	15.00 g	Nutritive component and osmolarity agent	MERIAL
	Dipotassium phosphate	1.25 g	Osmolarity agent	Ph.Eur.
	Potassium dihydrogen phosphate	0.46 g	Osmolarity agent	Ph.Eur.
	Phenol red	10 mg	pH indicator	MERIAL
	Sodium hydroxide or Hydrochloric acid concentrated	qs 6.9 ≤ pH ≤ 7.3	Adjustment of pH	Ph.Eur.
	Water for injections	q.s. 1 l	Solvent	Ph.Eur.
Constituents of the pharmaceutical form	NA	NA	NA	NA

NA: Not Applicable

Ph. Eur.: current European Pharmacopoeia edition

Container and closure

Frozen cell suspension:

The vaccine concentrate is filled into Type I glass ampoules of 2-ml and 5-ml (compliant with current European Pharmacopoeia (Ph. Eur.)), which are sealed using a flame.

Solvent for dilution:

The solvent is filled in heat-sealed bags with two connecting tubes, one for filling and one fitted with a septum for puncture. The bags are made of polyvinylchloride (250-ml, 500-ml, 1,000-ml, 2,000-ml and 3,000-ml volumes) complying with the current Ph. Eur. edition and can be filled with different volumes depending on the presentations:

Presentation (nominal volume)	Bag size
200 ml	250-ml bag
400 ml	500-ml bag
600 ml	1,000-ml bag
800 ml	1,000-ml bag
1,000ml	1,000-ml bag
1,200 ml	2,000-ml bag
1,600 ml	2,000-ml bag
1,800 ml	2,000-ml bag
2,400 ml	3,000-ml bag

Each bag is then placed in a polyethylene terephthalate metal (PETmet)/ cast polypropylen (CPP)/ polyethylen (PE) protective overpouch that is heat-sealed.

Product development

An explanation and justification for the composition and presentation of the vaccine has been provided.

Frozen cell suspension:

Prevexxion RN (in the dossier referred to as PHN3257 monovalent vaccine) is a live vaccine intended for vaccination against Marek's disease (MD) by subcutaneous administration to one-day-old chicks.

Boehringer Ingelheim Vetmedica GmbH has already registered a vaccine against MD, Cryomarex Rispens, which is currently used worldwide for years (first registrations in Europe more than 20 years ago, extended in 2014 through a mutual recognition procedure). Its active substance is the attenuated live Marek's disease virus (MDV), serotype 1, Rispens strain (CVI988). Merial has now developed the Prevexxion RN vaccine, containing serotype 1, RN1250 strain.

Development of the vaccine started in the USA, leading to a full market authorisation in 2017 for the monovalent RN1250 vaccine and in 2018 for the bivalent RN1250+vHVT013-69 vaccine. The vaccine for use in EU comes from the same master seed virus (MSV). The manufacturing process and some control analytical tools have been transferred in Lyon to guarantee equivalence of the products.

Choice of the vaccine strains

The MD vaccine strain, RN1250 was originally generated and tested at the USDA ARS, Avian Disease Oncology Laboratory (ADOL) in the USA before being transferred to Boehringer Ingelheim Vetmedica GmbH. RN1250 strain has been constructed by genetic engineering to generate a Marek's disease virus, serotype 1 (MDV1), strain CVI988 containing two copies of a long terminal repeat (LTR) sequence of a reticuloendotheliosis virus (REV). CVI988 Rispens vaccine strain is used in licensed vaccines worldwide and more particularly in Europe since the 1970s.

Thus, RN1250 strain includes in particular genomic parts:

- from the currently most efficacious and safe vaccine MDV strain, the CVI988 Rispens strain,
- from the MDV RM1 strain, derived from a virulent MDV strain (JM/102W) in the genome of which two copies of REV LTR were inserted.
- from the very virulent MDV Md5 strain, in which a fragment of MDV RM1 strain containing the REV LTRs was inserted.

RM1 was shown to have lost its oncogenicity potential and to be very efficacious as a vaccine against MD, properties thought to be linked to LTR insertion; however, it induced severe thymus and bursal atrophy. A chimeric virus was then generated from RM1 and CVI988 viruses in order to improve safety while keeping advantages of REV LTR. To create this chimeric virus, the RM1 genomic region containing the REV LTRs was cloned into a cosmid vector already containing a fragment of very virulent Marek's disease virus (vvMDV) Md5 strain (B40 cosmid). The RM1 REV LTRs and flanking sequences were then transferred from the cosmid vector into the corresponding region of the MDV vaccine CVI988 genome to get a new safe and efficacious MD vaccine.

Choice of the antigen manufacturing process and active substance quantification method

The manufacturing process chosen for the RN1250 antigen is classical of this type of vaccine, similar to antigens used in other vaccines against Marek's disease. The antigen is a suspension of specific pathogen-free (SPF) chicken embryo fibroblasts infected with RN1250. The virus used for the inoculation of the production culture is amplified by passages in SPF chicken embryo cells in roller bottles. The infected cells are harvested using trypsin and centrifuged. At the last passage, the cell pellet is suspended in dilution medium and calf serum. The cell suspension is then sieved and constitutes a batch of active ingredient to be used within one day with storage at 5°C ± 3 °C if applicable. No quantification of the active ingredients is performed before formulation as the active

ingredients are used within one day in the vaccine formulation. RN1250 active ingredient is titrated in the finished product according to the induction of a cytopathic effect revealed in the form of foci (called PFU or plaque forming units) after inoculation on chicken embryo fibroblasts, as classically done for Marek's vaccines. PFU are revealed by indirect immunofluorescence using specific monoclonal antibodies against respectively a protein expressed by serotype 1 MDV for RN1250.

Finished product presentation

The vaccine is presented in the form of a sealed glass ampoule containing the frozen antigen suspension to be diluted in the solvent used for the preparation of Boehringer Ingelheim Vetmedica GmbH cell-associated poultry vaccines, presented in PVC bags. RN1250 are cell-associated viruses and are present in very small concentrations in the supernatant of infected cell cultures. The freezing process used avoids the destruction of host cells and thus allows a stable storage of the vaccine. Three presentations are proposed:

- a 1,000-dose presentation corresponding to 2 mL antigen suspension to be diluted in 200 mL solvent.
- a 2,000-dose presentation corresponding to 2 mL antigen suspension to be diluted in 400 mL solvent.
- a 4,000-dose presentation corresponding to 4 mL antigen suspension to be diluted in 800 mL solvent.

Choice of excipients

The vaccine excipient dimethyl sulfoxide (DMSO) was selected for its capacity to protect cells infected by the vaccine virus during freezing.

Choice of containers

The container constituents for the vaccine suspension (type I glass ampoule) were selected for their pharmaceutical quality and their compliance with the Ph. Eur. requirements. The containers are also suitable for liquid nitrogen storage.

Definition of the specifications

For RN1250: The minimum protective dose was set at 2.9 log₁₀ PFU/dose, according to the results of the efficacy studies. The minimum release titre was set to 0.3 log₁₀ above the minimum protective dose, i.e. 3.2 log₁₀ PFU/dose, according to the results of the stability studies.

The maximum release dose was set to 3.9 log₁₀ PFU/dose, based on the results of the safety studies.

MDV1 and HVT strains have been shown in the studies presented as well as in published literature (Gimeno, 2019) to influence each other. For protection against MD, the viruses appear to complement each other but if additional epitopes of other viruses are inserted in a genetically engineered HVT strain (such as IBD protein VP2 in this case) production of these proteins may be reduced or delayed. In study 19.0162.R, IBD protection was lower when the RN1250:vHVT013 titre ratio was 2:1 instead of 1:4 while it was similar when this ratio was between 1:1 and 1:4 (study 2019147).

Solvent for dilution:

The solvent is a saline solution supplemented with different components which act as a nutritive component (sucrose), protective agent during the reconstitution of the vaccine (casein hydrolysate), osmolarity agents (sucrose, potassium dihydrogen phosphate, dipotassium phosphate), or are used to adjust the pH (hydrochloric acid, sodium hydroxide). The phenol red allows an additional control that the pH is within acceptable limits. Casein hydrolysate is the only starting material of animal origin. Casein hydrolysate is a bovine milk derived product used since it was necessary to protect the live virus

during the reconstitution of the vaccine with the diluent. All these starting materials were treated by gamma radiation.

Choice of containers

The container constituent (polyvinylchloride bag) was chosen for its pharmaceutical quality and compliance with the Ph. Eur. requirements. Furthermore, this material, being heat-resistant, is appropriate for steam sterilisation. After sterilisation step, each PVC bag is placed in a PETmet/ CPP/PE overpouch which protects the bag from possible water losses.

Description of the manufacturing method

RN1250 component

The active ingredient is a suspension of MDV SR-1 RN1250, multiplied in SPF chicken embryo cells. A seed lot system is used for the preparation of active ingredients. Batches of active ingredient consist of the 5th passage at most in SPF chicken embryo cells, from the MSV. Virus and chicken embryo cells are cultured simultaneously in roller bottles. After incubation for 2 to 5 days, when the cytopathic effect caused by the virus is optimum, the cells are harvested, centrifuged and diluted with 18% of calf serum and sieved. The cell suspension constitutes a batch of active ingredient and is used within 1 day.

Frozen cell suspension

Formulation is based on volume. The active ingredient, RN1250, is stirred. Dimethyl sulfoxide is mixed with an equal volume of dilution medium, cooled down, and added to the active ingredient under stirring while kept between +1 °C and +10 °C. The bulk product is filled into sterilised ampoules. Ampoules are subsequently sealed using a flame. Filled ampoules are frozen to at least -120 °C and stored in liquid nitrogen.

Solvent for suspension for injection

The different constituents of the diluent (sucrose, casein hydrolysate, dipotassium phosphate, potassium dihydrogen phosphate) are blended and stirred for a few minutes. After the addition of phenol red and of water, the pH is adjusted to between 6.9 and 7.3 using NaOH or HCl. Then, water is added to reach the final volume. The bulk obtained is maintained under stirring at room temperature until filling, for at least 20 minutes. The bulk product is filled into containers that are already labelled. A terminal sterilisation process is used after the filling step by autoclaving. Bags are then stored at room temperature until they are completely dry. Then, each bag is placed in a PETmet/ CPP/PE overpouch. Immediately after addition of the overpouch, the secondary packaging is carried out. After secondary packaging, the diluent is stored at room temperature.

All steps of the manufacturing process have been validated. It has been demonstrated that the manufacturing process is capable of producing finished product of the intended quality in a reproducible and consistent manner. The in-process controls are adequate for this type of manufacturing process.

Production and control of starting materials

Starting materials listed in pharmacopoeias

The starting materials for the production of the frozen cell suspension that are listed in a pharmacopoeia are presented in the table below.

Summary table of starting materials used for the preparation of the frozen vaccine suspension	
Starting materials	Used for
Calf serum and donor calf serum	Preparation of the active ingredient (RN1250)
Dimethyl sulfoxide	Preparation of frozen vaccine suspension
Gentamicin sulphate	Preparation of the culture medium (A44) Preparation of SPF chicken embryo cells
Glass containers for pharmaceutical use	Packaging of the frozen vaccine suspension
Iron fortified calf serum	Preparation of the culture medium (A44)
Purified water	Preparation of the culture medium (A44)
Sodium hydrogen carbonate	Preparation of the culture medium (A44) Preparation of the dilution medium (A41)
SPF embryonated hen eggs	Preparation of SPF chicken embryo cells
Water for injections in bulk	Preparation of the dilution medium (A41)

The starting materials for the production of the solvent that are listed in a Pharmacopoeia are presented in the table below.

Summary table of starting materials used for the preparation of the solvent	
Starting materials	Used for
Dipotassium phosphate	Preparation of the solvent
Hydrochloric acid concentrated	Preparation of the solvent
Polyvinylchloride bags	Packaging of the solvent
Potassium dihydrogen phosphate	Preparation of the solvent
Sodium hydroxide	Preparation of the solvent
Sucrose	Preparation of the solvent
Water for injections in bulk	Preparation of the solvent

Specific materials not listed in a pharmacopoeia

Starting materials of biological origin

Frozen cell suspension

The starting materials of biological origin for the production of the frozen cell suspension that are not listed in a Pharmacopoeia are presented in the table below.

Summary table of starting materials used for the preparation of the frozen vaccine suspension	
Starting materials	Used for
MDV SR-1 RN1250 component	Preparation of the active ingredient (RN1250)
SPF chicken embryo cells	Preparation of the active ingredient (RN1250)
Recombinant trypsin	Preparation of SPF chicken embryo cells Preparation of the active ingredient (RN1250)
Trypsin (porcine origin)	Preparation of SPF chicken embryo cells Preparation of the active ingredient (RN1250)
Tryptose Phosphate Broth (TPB)	Preparation of the culture medium (A44)

RN1250 master seed virus

RN1250 is an engineered Marek's disease virus based on the MDV CVI988 parental vaccine virus that contains two copies of reticuloendotheliosis virus (REV) long terminal repeats (LTR) from MDV RM1 strain inserted in its genome. The RN1250 recombinant virus was generated by in vitro homologous recombination. The sequence analysis confirmed that the RN1250 selected clone is a virus containing MDV genomic segment from three different MDV viruses (see Figure below):

1. The TRL-UL-IRL from CVI988 parental virus,
2. The distal IRS and TRS sequence (up to PacI site) from Md5,
3. The proximal IRS and TRS sequences (from the PacI site) and US from RM1.




Figure: Genomic structure of the chimeric RN1250 genome: CVI988 sequence are shown in dark blue, Md5 sequences are shown in magenta and RM1 sequence is shown in green. The latter contains the REV LTR sequence shown in red.

The MSV was qualified using the following tests: bacterial and fungal sterility, mycoplasma, identity (by PCR), virus titre and viral purity (as described in and in compliance with Ph. Eur. 2.6.24: Avian viral vaccines, tests for extraneous agents in seed lots). The working seed virus (WSV) is obtained from the MSV by carrying out passages in SPF chicken embryo cells. The WSV corresponds to the 4th passage at most from the MSV. The WSV was qualified using the following tests: bacterial and fungal sterility, mycoplasma, identity (by PCR) and virus titre. Both the MSV and WSV are stored frozen in liquid nitrogen.

The genetic stability of RN1250 was evaluated by comparing the genome structure of the RN1250 master seed virus (MSV) with that of RN1250 passaged 5 times in CEF cell cultures (X+5) or 5 times in chickens (back passages; BP5). PCR, Southern blot and sequencing of the genomic regions around the LTR insertion (including each junction of RS (IRS and TRS) with US) showed no difference between the 5th in vitro (X+5) and in vivo (BP5) passaged viruses and the MSV, indicating RN1250 genetic stability. A deep sequencing of two of the monovalent RN1250 batches (1632575B021 (B021) and 183257A5X21 (5X21)) produced at MSV+5 levels showed a very high sequence homology (>99.6 %) between the 2 MSV+5 vaccine batches.

Solvent

The only starting material of biological origin for the production of the solvent that is not listed in a Pharmacopoeia is: casein hydrolysate. The casein used for casein hydrolysate preparation is made from bovine milk that is sourced from healthy animals originating from bovine spongiform encephalopathy (BSE)-free regions of the USA, New Zealand, Australia and Canada in accordance with the requirements of the European Note for Guidance on "Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products". The casein hydrolysate is irradiated ($\geq 35\text{kGy}$).

Starting materials of non-biological origin

The starting materials of non-biological origin for the production of the frozen cell suspension that are not listed in a pharmacopoeia are: hydrochloric acid solution, A44 culture medium and A41 culture medium.

The only starting material of non-biological origin for the production of the solvent is Phenol red (1% solution).

In-house preparation of media and solutions consisting of several components

Composition of media used during production was provided.

The applicant provided a detailed description of the starting materials.

Control tests during the manufacturing process

Frozen cell suspension

Cultures and harvests are visually inspected. No control tests are carried out on the active ingredient as RN1250 is used within one day after harvest.

Time is recorded during mixing and homogenising of active ingredient and excipients in the final formulation. Volume is measured during filling of finished product in vials. Filled vials are checked for appearance. During freezing of vials, time and temperature are recorded.

Solvent

Time is monitored during blending, sterilisation and drying. Osmolality and pH are measured at the level of the final bulk. Volume is measured during filling in bags. Terminal sterilisation is monitored. Temperature is recorded during drying. The finished product is checked for appearance.

Control tests on the finished product

The tests to be performed on the finished product (frozen cell suspension) are presented in the table below.

Summary table of control tests and requirements applicable to the frozen vaccine			
2.E.	Technique	No.	Limits of acceptance
1	Appearance	10001	Yellow to reddish pink opalescent homogeneous suspension
	pH	10010	$7.0 \leq R \leq 8.0$
	Volume	10011	$1.9 \leq R \leq 2.1$ ml for 1000 and 2000 doses $3.8 \leq R \leq 4.2$ ml for 4000 doses
2	Identity of RN1250 AI	200867	Specific amplification
3	Titration of RN1250 AI	200831	$3.2 \leq R \leq 3.9$ log ₁₀ PFU/dose
7	Bacterial and fungal sterility	11000	No growth
	Mycoplasmic sterility	200814	No detection
	Viral purity	200011	No CPE, no HA, no HAD
		200012	Absence of embryo abnormalities or death
		200025	Absence of chicken anemia virus
		200026	Absence of egg drop syndrome virus
200027	Absence of Marek's disease virus*		
200028	Absence of turkey rhinotracheitis virus		
AI: Active ingredient R: Expected result CPE: Cytopathic Effect HA: Haemagglutination HAD: Haemadsorption			
* Except when the virus to be detected is the vaccine strain.			

The tests to be performed on the finished product (solvent) are presented in the table below.

2.E.	Technique	No.	Limits of acceptance
1	Appearance	10001	Red-orange limpid solution
	pH	10010	$6.4 \leq R \leq 7.8$
	Volume	10011	- 200ml presentation: ≥ 215 ml
			- 400ml presentation: ≥ 430 ml
		- 600ml presentation: ≥ 644 ml	
		- 800ml presentation: ≥ 859 ml	
		- 1000ml presentation: ≥ 1073 ml	
		- 1200ml presentation: ≥ 1288 ml	
		- 1600ml presentation: ≥ 1717 ml	
		- 1800ml presentation: ≥ 1932 ml	
		- 2400ml presentation: ≥ 2576 ml	
	Cryoscopic depression	10017	$-0.55 \leq R \leq -0.47$ °C
7	Bacterial and fungal sterility	11000	No growth

For each analytical method a description was provided.
For non-pharmacopoeial methods validations were provided.

Batch-to-batch consistency

The applicant presented final product data for the manufacture of at least three consecutive final product batches (both frozen cell suspension and solvent). The results were compliant with the specifications as mentioned in the tables above.

Stability

No stability data were provided for the active ingredient, which is acceptable as it is not stored but immediately processed into finished product.

Frozen cell suspension

Long-term stability was followed on two different formulations:

- 1) Three batches of Marek's Disease Vaccine, serotype 1, live virus (Product Code 16L1.R0) manufactured at MERIAL Inc. manufacturing site (USA) and stored during 39 months in liquid nitrogen. The US vaccine coded 16L1.R0 above has been manufactured from the same EU MSV (RN1250) as the Prevexxion-RN vaccine. Manufacturing processes between the US and EU vaccines are similar. Titration method is also similar to the EU one.
- 2) Six batches of Prevexxion RN manufactured at Boehringer Ingelheim Animal Health - Porte des Alpes manufacturing site (France) and stored up to 27 months in liquid nitrogen.

The US batches were tested for potency up to 39 months. For the EU batches data up to 27 months are available. Whereas the US batches have a slightly higher titre (outside the specifications of the EU product), it is acknowledged that these lots can be considered as representative given the highly similar manufacturing process. A slightly higher titre is not expected to have any impact on the stability profile or any stability trends. Potency remained also very stable for the US batches. Therefore, it is agreed that data from the US lots can be used to qualify the proposed shelf life of 36 months. In conclusion, a shelf life of 36 months storage in liquid nitrogen can currently be accepted.

The in-use stability of the reconstituted vaccine was evaluated after reconstitution of the thawed viral suspension in the solvent. Titration results show that the vaccine must be used within 2 hours at room temperature after reconstitution.

Solvent

The solvent has been historically used to reconstitute all Boehringer Ingelheim Animal Health cell-associated Marek's disease vaccines. Since many years and up to early 2018, this solvent was provided by Baxter healthcare. This solvent was granted a 36-month shelf life based on the following stability study: *Document Final report A00131 "Stability study of diluent SHC Marek in bags", AVOGADRO 5 March 2004*. The stability study was carried out on six batches of solvent bags manufactured by BAXTER Healthcare. Except for the extractable volume and pH, the long-term stability results of the solvent manufactured by BAXTER Healthcare do not show any change after 36 months of storage at $25 \pm 2^\circ\text{C}$ with $60 \pm 5\%$ of humidity. The decrease in pH over time was taken into account in the product specifications (the inferior limit of acceptance for pH at release (pH 6.4) is higher than that applicable at the end of shelf life (pH 5.8) and a filling overage is applied during the manufacturing process to guarantee that the minimal volume specification of each bag is met until the end of shelf life.

Very recently, the production of this solvent was successfully transferred to a new sub-contractor: Bioluz Laboratory.

A new stability study was launched on six batches of sterile solvent manufactured in Bioluz Laboratory with 3 consecutive batches of 200 ml bags and 3 consecutive batches of 1,200 ml bags. The stability results obtained under long-term test conditions do not show significant change after 18 months of storage for all the tested parameters, except for pH and extractable volume. As expected, a slight decrease in pH results is observed for all formats but all results remain within the specifications. A decrease of extractable volume is observed for all presentations. More specifically, the maximum water losses observed are of 10 mL for 200 mL format and 45 mL for 1200 mL format, below the current approved over-filling volumes. Thus, despite this volume decrease, the volumes remain within the approved specifications. The proposed shelf life of 36 months for the solvent is acceptable, but it should be completed with product batches produced in Bioluz including one batch of a 2400 ml volume (Recommendation). The applicant has committed to provide these data when available.

Overall conclusions on quality

The applicant has provided an extensive description of the composition of the vaccine, which consists of a frozen component with the active substance (RN1250 within chicken embryo cells) and a solvent. Information was provided on the different containers for active substance and solvent. The product development section describes the choice of the antigen, excipients and containers, as well as the virus titre specification limits. The proposed specifications for the RN1250 vaccine strain are acceptable.

The manufacturing process of the active substance (RN1250 within chicken embryo cells) and the final vaccine were sufficiently described.

All starting materials were listed and certificates of analysis were provided (where applicable). As regards starting materials of biological origin, a detailed description was provided of the vaccine virus strain (RN1250). Virus seeds were properly qualified and shown to be genetically stable (for at least 5 passages).

An overview was provided of the control tests performed during manufacturing and of the control tests performed on the finished product.

Batch data were provided for 3 consecutive batches of the frozen cell suspension component and the solvent, confirming the validated status of the manufacturing processes. Also, homogeneity during formulation and filling was properly validated.

To support the proposed shelf life of 36 months, the applicant provided supportive stability data of a vaccine formulation approved in the US (containing RN1250). Sufficient justification was provided that this vaccine can be considered as representative. The proposed shelf life of 36 months for the solvent is acceptable, but should still be completed with product batches produced in Bioluz and also for one batch of a 2400 ml volume (Recommendation).

In conclusion, based on the review of data on quality, the manufacture and control of Prevexxion RN can be considered acceptable.

Part 3 – Safety

Introduction and general requirements

Prevexxion RN is a vaccine containing a cell associated live GMO vaccine strain, an engineered Marek's

disease virus (MDV-1) serotype 1, named RN1250 strain. The vaccine intended for a single administration to one-day-old broiler or laying chicks by the SC route.

Safety documentation

Prevexxion RN has been developed both in the US and EU and has been on US market since 2017. A total of 9 studies were carried out in the US. The similarity between RN1250 manufactured in the US and the one manufactured in the EU has been proven by appropriate documents.

The safety profile of Prevexxion RN is supported by 13 laboratory studies and 3 field studies. Requirements listed by Ph. Eur. monograph 0589 for MD (live) were fulfilled as well as general requirements of the Ph. Eur. general chapter 5.2.6 Evaluation of safety of veterinary vaccines and immunosera and in Directive 2001/82/EC. According to special requirements for live vaccines, studies were provided on the spread of the vaccine strain from vaccinated chickens to contact target species and non-target species, as well as the spread from non-target species to non-target species. Studies were provided also on dissemination in the vaccinated animals, on reversion to virulence, on biological properties and recombination or genomic re-assortment of the vaccine strains.

Trial	Injected dose in log ₁₀ PFU		Route	Type and total number of animals included	Age of animals
	RN1250	vHVT013			
LABORATORY TESTS					
<i>Safety of the administration of one dose and of an overdose</i>					
16.0388.R	3.9 and 4.9	4.6 and 5.6	SC	105 SPF chicks	1-day-old
<i>Examination of reproductive performances</i>					
16.0202.R	3.5	4.1	SC	55400 conventional pullets	1-day-old
<i>Examination of immunological functions</i>					
10-156	3.7 (5144)	-	SC	250 SPF chicks	1-day-old
<i>Spread of the vaccine strains</i>					
10-065	5.0 (100000)	-	SC	90 SPF chicks	1-day-old
16.0204.R	4.3	-	SC	70 SPF chicks	1-day-old
<i>Dissemination in the vaccinated animal</i>					
10-065	5.0 (100000)	-	SC	90 SPF chicks	1-day-old
10-066	3.9 (8000)	-	SC	40 SPF chicks	1-day-old
16.0204.R	4.3	-	SC	70 SPF chicks	1-day-old
<i>Reversion to virulence of attenuated vaccines and residual pathogenicity assessment</i>					
10-130	3.8 (6400)	-	IP	205 SPF chicks	1-day-old

Trial	Injected dose in log ₁₀ PFU		Route	Type and total number of animals included	Age of animals
	RN1250	vHVT013			
15.0408.R	4.3	-	IO	102 SPF chicks	18 days of incubation
16.0013.R	5.3	-	SC	145 SPF chicks	1-day-old

Biological properties of the vaccine strains					
12-012	3.8 (6000)	-	SC	42 SPF chicks	1-day-old
11-036	4.7 (53440)	-	SC	80 quails, 80 turkeys, 80 ducks, 80 pheasants, 80 pigeons and 20 chickens	1-week-old quail, turkeys, ducks, and pheasants, 6-12 month old pigeons and 1-day-old chicks
11-090	4.5 (33744) by SC and 4.6 (44304) by ES	-	SC/ES	21 SPF mice	6-7 weeks
Trial	Injected dose in log ₁₀ PFU		Route	Type and total number of animals included	Age of animals
	RN1250	vHVT013			
Recombination or genomic reassortment of strains					
11-069	4.0	-	SC	300 SPF chicks	1-day-old
Interactions					
16.0388.R	3.9 and 4.9	4.6 and 5.6	SC	105 SPF chicks	1-day-old
FIELD STUDIES					
16.0201.R	3.6		SC	17530 conventional chicks	1-day-old
	3.5	4.1			
16.0202.R	3.6		SC	55400 conventional pullets	1-day-old
	3.5	4.1			
16.0200.R	3.5		SC	830 conventional chicks	1-day-old
	3.5	4.1			

SC: subcutaneous; IP: intraperitoneal; IM: intramuscular; IO: in ovo; ES: epidermal scarification

Laboratory tests

Safety studies were reported in compliance with Good Laboratory Practice (GLP) standards except for the US studies which complied to US regulation.

Safety of one administration of one dose and of an overdose

The study 16.0388.R investigated the vaccine at 1 and 10 times its highest titre. Day-old SPF Leghorn chickens (35 for each dosage), the most susceptible birds, were vaccinated at the lowest age recommended in the SPC. Mortality and morbidity were monitored over 21 days and all dead birds were necropsied.

Birds were properly vaccinated since RN1250 vaccine strain was detected in the spleen of all the vaccinates on day 7.

Three unspecific early fatalities were observed in the control group and in the group vaccinated with the overdose. No local reactions were detected. No MD related signs or gross lesions were noticed. A mean 5% bodyweight growth retardation (11.8 g) was found out at the end of the observation period

(day 21) with the overdose vaccination.

As the study is not compliant with Ph. Eur. 0589 requirements for residual pathogenicity, because the monitoring was shorter, fewer birds were included, another overdose study (19.0160.R) with the combined product was performed.

One-day old SPF chickens (45) were vaccinated with a 10X overdose of the vaccine and monitored over 120 days; their body was weighted on D0, D8, D61 and D120. The chicken breed was fully susceptible to Marek virus since 89% get the disease after a challenge with a virulent MDV strain. Birds were properly vaccinated since RN1250 vaccine strain was detected in the spleen of all the vaccinates on day 7. Neither clinical signs nor mortality was observed while a transient (day 8 only) and slight (5%) growth slowdown was reported. This transient adverse event has been included in section 4.10 of the SPC.

Safety of the repeated administration of one dose

The repeated administration of the vaccine was not studied because it is intended to be administered once to each bird.

Examination of reproductive performance

The safety on the reproductive performance of layers has been addressed in a field study (16.0202.R) where both RN1250 and RN1250+vHVT013-69 vaccines were compared to Nobilis Rismavac+CA 126, an authorised vaccine with the same combination of valences or RN1250 associated with Cryomarex HVT. Two different breeds of pullets (LSL Classic and Hy-Line Brown Rural) were monitored up to 30 weeks of age (12 weeks after they have started laying), each one in a multiple-site production system of 2 farms.

The take of the vaccine was confirmed as the vaccine strain RN1250 was amplified by PCR overall in 67% of the spleens of the vaccinated groups sampled on day 8-9.

No difference between vaccines on the quality and the number of eggs was reported in pullets vaccinated according to the proposed SPC (D0) long before laying. See Part III C. for the complete report of this study.

In conclusion, the vaccine can be administered safely to future layers and a proper warning include in the SPC reminds that the vaccine is intended to be administered to 1-day old chickens.

Examination of immunological functions

In study 10-156 the repercussion of RN1250 vaccine strain on the immune system was compared to the one of an US licensed vaccine (Rismavac) in a USDA compliant study. The anatomy of 3 organs of the immune system, the thymus, the bursa of Fabricius and the spleen was investigated at 7, 14, 28 and 49 days after vaccination in vaccinates (groups of 50 birds), in contact control birds or in controls reared without contact with vaccinates. The birds included in the study were SPF and vaccinated at one day of age, the lowest age of vaccination. RN1250 was administered at the highest passage (x5) and dosed just below the maximum release titre (3.7 instead of 3.9 PFU/dose) and Rismavac was at an equivalent titre (3.8 log₁₀ PFU/dose).

No MDV-like gross lesions were reported.

The immune organs/body weight ratios did not differ between RN1250 vaccinates and both control groups. On day 7 a mild to moderate lymphocyte depletion in the thymus (mean score of 2.3) was

reported in both vaccines. An increase of germinal centres of the spleen was reported 4 weeks after vaccination in both vaccinate groups as well as RN1250 contact control group, which was probably caused by antigen stimulation of a subclinical infection.

Morphologically, RN1250 near its maximum titre had a slight and transient impact on the thymus.

To check whether lymphocyte depletion of the thymus at D7 (study 10-056) could portends a functional impairment of the immune system, the efficacy of NDV vaccination at day 7 of 80 birds further Prevexxion RN+HVT+IBD or Prevexxion RN vaccination was challenged in study 19.0161.R. Both Prevexxion vaccines were near their maximal titres and NDV vaccine was a commercial one used according its label. Chickens were challenged 2 weeks later by a virulent NDV strain. While 100% of NDV non-vaccinated birds died within 2 days, 100% of the vaccinates were protected. In conclusion the vaccine does not impaired the functioning of immune system as checked throughout its response to NDV vaccination.

In conclusion, despite a moderate lymphocyte depletion in the thymus transient at day 7, the immune system was able to mount a protective response to Newcastle disease virus demonstrated by a challenge 2 weeks later, suggesting that no functional immunosuppression is caused by vaccination with Prevexxion.

Special requirements for live vaccines

Dissemination in the vaccinated animal

In study 10-065, the dissemination of RN1250 vaccine at a 10-time overdose and MSV+5-passage in one-day-old SPF chickens was compared with that of a commercial vaccine composed of a Rispens strain (Merial Select's SR-1 Rispens). In addition, its spreading potential was investigated by allowing contact of the vaccinates with hatch mates (contacts) in a ratio of 3 to 1. Birds were investigated 2, 3, 4 and 7 weeks after vaccination and monitored for clinical signs of MD daily. Tracheal and cloacal swabs were taken from 30/30 birds per group while feather follicles of 2/30 birds per group were collected. The spleen of 5 contact and 5 vaccinates was drawn 3 and 7 weeks after vaccination.

No vaccine strains were isolated from contact birds. The spleen of vaccinates was not investigated. Rispens MD strain was isolated from the feather follicles of 2/2 bird 21 days after vaccination only, conversely to RN1250 which was never isolated. Neither Rispens nor RN1250 MDV strains were isolated from tracheal or cloacal swabs. Finally, MDV was never isolated from the spleen of birds in contact with Rispens or RN1250 MDV strains nor was it amplified by SR-1 MD PCR at the completion of the study (7 weeks) suggesting that there was no spread to contacts.

In the study 10-066, the distribution of RN1250 in the spleen, liver, lungs, kidneys, and gonads was compared to the one of a commercial vaccine, Merial Select's SR-1 Rispens vaccine, in day-old SPF SPAFAS chickens (15/group). RN1250 was injected S.C. at the highest recommended dose and passage (3.9 log₁₀ PFU/dose; MSV+5). One and 4 weeks after vaccination, spleen, liver, lungs, kidneys, and gonads where sampled from 5 vaccinates.

RN1250 was isolated from 1/5 spleen at day 28 while Rispens strain was isolated from 4/5 spleens both at day 7 and 28 as well as from few lungs, kidney, liver samples and even one gonad sample.

In study 16.0204.R, a group of 35-day-old Leghorn SPF chickens were subcutaneously vaccinated in the neck with 4.3 log₁₀ PFU, a vaccine amount above the maximum recommended dose and at MSV+2 passage. Another group of 35 hatch mates which were left unvaccinated was put in contact with the vaccinated birds in the same unit of cages from the start of vaccination (D0) onward.

The dissemination of RN1250 vaccine strain in blood, spleen and feathers was checked weekly over 6 weeks, at 7, 14, 21, 28, 35 and 42 days after vaccination, in 5 vaccinated chickens and 5 contact chickens at each time point. RN1250 specific real-time PCR was carried out in blood, spleen and feathers samples which are known to be the most susceptible organs to MDV infection. In addition, the presence of RN1250 vaccine strain was investigated in the environment using the same technique carried out on dust samples taken on D21 and D42.

No clinical signs were observed except pecking in birds in day 35 which were preferentially chosen for sampling and no mortality was recorded.

RN1250 vaccine strain DNA was amplified in the blood 7 days after vaccination, in the feather follicles up to day 21 and in the spleen up to the completion of the study (day 42). It was also amplified in the dust from the air filter on day 21 in coherence with feather results. On the other hand, it was detected in contact birds in none of their spleen except one doubtful result.

This study showed that RN1250 vaccine strain DNA can be found in the skin and in dander in the dust aerosol but without biological significance for contact birds.

In conclusion, RN1250 strain was not isolated by cell culture from feathers in any of the studies (10-065, see also study 12-012 below). However, RN1250 DNA was detected in feathers 1 and 3 weeks after vaccination which was corroborated by environmental dust samples of the same study (16.0204.R). Conversely, Rispens strain was isolated from 2/2 feather samples 3 weeks after vaccination. RN1250 DNA was not amplified from cloaca and trachea swabs (16.0204.R).

In internal organs, spleen was the organ where RN1250 strain was isolated the longest time (still detected 7 weeks after vaccination) and conversely to the serotype 1 vaccine strain (Rispens), RN1250 was not isolated from gonad, kidney, liver lung 1 or 4 weeks after vaccination (study 10-066).

Spread of the vaccine strain

In study 10-065 described in section B.6.1., where 10 birds were put in contact with 30 vaccinates with an overdose of RN1250 or a commercial vaccine, Merial Select's SR-1 Rispens, no MDV strain was isolated from the spleen of contacts nor was it amplified by SR-1 MD PCR at the completion of the study (7 weeks) suggesting a lack of live virus spread to contacts.

Study 16.0204.R corroborated the lack of spread reported in study 10-065. The spread of the vaccine strain to contact hatch mates was monitored with a RN1250 specific real-time PCR on the spleen of contact birds sampled 7, 14, 21, 28, 35 and 42 days after vaccination at one-day old. RN1250 was detected in none of these spleens except one doubtful result (for a complete report of the study see section B.6.1).

In the reversion to virulence study (10-130), 5 naïve birds were put in contact with 15 vaccinates at each passage of the vaccine strain. The vaccine strain was never isolated from the blood of the contact while it was from the blood of vaccinates.

In conclusion, the spread of RN1250 strain has been examined in 3 studies. Except one doubtful result with RN1250 nucleic amplification in study 16.0204.R, RN1250 vaccine strain was neither isolated nor amplified in the spleen of birds in contact with birds vaccinated with the highest recommended dose of vaccine or above.

Reversion to virulence of attenuated vaccines

In study 10-130, reversion to virulence was monitored over 5 sequential passages of the MSV RN1250

in 15 one-day old chickens administered IP and the passage 5 was compared to the initial strain (MSV) in 20 one-day old chickens, in a last study step as recommended in Ph. Eur. 0589. The initial birds were administered with 3.8 log₁₀ PFU and then 0.25 ml of white blood cell was injected to birds at each passage.

While RN1250 vaccine strain was passed successfully over the 5 passages, it was isolated from vaccinate white blood cell of passages 2, 3, 5 but did not at passage 1 and 4. The absence of multiplying RN1250 virus in the white blood cells of the 1st passage was corroborated both by cell culture isolation and by PCR at the last study step when it was compared to the passage 5 strain.

Contact birds were put together with vaccinates and RN1250 vaccine strain was never isolated from them.

At each passage, the clinical surveillance of 10 vaccinates (or 20 for the last step) lasted 49 days and none showed clinical signs or lesions associated with MD.

Another reversion to virulence study (15.0408.R + 16.0013.R) was performed, which complies with Ph. Eur. 0589 requirements. The passages (15.0408.R) were performed in SPF Leghorns birds which were inoculated *in ovo* with RN1250 (MSV+2) with a titre of 4.3 log₁₀ PFU above the highest recommended titre (3.9 log₁₀ PFU/dose). Then in-vivo passages were done every 7 days by IP administration with white blood cells taken from all the birds of the previous in-vivo passage. The vaccine strain was passed over 5 in-vivo passages.

No impact on the hatchability was observed at first inoculation. Neither clinical sign nor MD lesions were reported over the 7 days of surveillance.

The vaccine strain was isolated by cell sub-culture at first in-vivo passage (G1). It was necessary to have a second in-vivo passage to reach the cytolytic level of virus load (G2). From the 3rd in-vivo passage onwards, the vaccine strain virus was isolated upon first cell culture passage suggesting an increase of fitness of RN1250.

The investigation of any reversion to virulence of passage 5 was then undertaken in study 16.0013.R. While a slight reduction of growth (around 6%) was reported transiently for RN1250 P5, 8 and 61 days after administration, its intrinsic pathogenicity was not increased since no MD signs or lesions were reported when 20 vaccinates were monitored over 121 days.

In conclusion, while the RN1250 fitness was increased, by 5 in-vivo passages, neither an increase of virulence according to Ph. Eur. criteria (study 16.0013.R) nor spread to contact birds (study 10-130) were reported. These results have been corroborated by pharmacovigilance from non-EU countries where this vaccine is already marketed. Information is included in SPC section 4.5 about the potential spread of the vaccine strain.

Biological properties of the vaccine strain – Residual pathogenicity

In study 16.0013.R, the pathogenicity of RN1250 strain at passage 5 (P5) embedded in white blood cell (around 3.5 PFU/chick) (obtained from study 15.0408.R) was compared to that of the initial RN1250 strain (MSV+2) at more than 10 time overdose and to that of vvMDV strain (RB1b) and to control birds. One-day-old Leghorn chickens (at least 50) were administered with these strains (5.3 log₁₀ PFU MSV+2 RN1250) and monitored over a 121-day period except those injected with RB1b strain. Indeed 19 birds injected with RB1b strain died or were euthanized until day 70 and 22/26 remaining birds had MD-related lesions. Birds included into this study were thus fully susceptible to MDV since RB1b strain caused MD in 86.7% of the birds.

The adequate take of the vaccine was confirmed since the vaccine strains were detected by PCR in the spleen of 5/5 and 3/5 birds injected with RN1250 (MSV+2) and RN1250 P5 respectively. Viraemia was

detected by virus isolation on cell culture when RN1250 (MSV+2) was injected and was not with RN1250 P5.

No growth retardation was noticed 121 days after vaccination by comparison to controls. On D8 significant differences in body weight between G1 (received MSV+2) and G2 (received passage 5) as well as differences in virus isolation in the blood were found.

Results of body weight were not interpretable at D8 because several chickens lost their wing tags in groups GA, G1 and G2 after weighing at D8) could have biased the statistical analysis.

Several birds were sick in vaccinate group. However, MD suspicions were ruled out due to the absence of specific macroscopic and microscopic lesions (5 birds).

In conclusion, in this study which is compliant to Ph. Eur. 0589, the master seed RN1250 virus at passage 2 (MSV+2) exhibited no residual pathogenicity nor was different from the strain collected further 5 in-vivo passages in birds.

Biological properties of the vaccine strains – Replication particularities

In study 12-012, RN1250 close to its highest titre (3.8 log₁₀ PFU/dose) was administered to one-day-old SPF chickens and its dissemination at day 7, 14 and 49 was compared to the one of a commercial vaccine, Merial Select's SR-1 Rispens, at the same titre.

The chickens were susceptible to MD infection since Rispens vaccine strain was isolated or amplified over the 49 days of monitoring both in internal organs and feathers in line with the biology of this strain; viral particles were still isolated from the spleen of 2/5 birds, 49 days after administration.

RN1250 was isolated from 1 kidney, 1 liver 2 blood and 2 spleen samples until day 14 while it was not in the feather; RN1250 was amplified by a specific RN1250 PCR, from 6/6 spleen samples, 5/6 blood samples, 2/5 kidney samples, 2/4 liver samples and 2/4 lung samples. However, since lot of results from PCR detections were missing and RN1250 PCR was much more sensitive than virus isolation and conventional serotype 1 MDV PCR, no firm conclusion regarding the presence of RN1250 vaccine strain can be drawn from this study, especially in feathers. However, this study confirms that RN1250 caused viraemia which lasted between 2 and 7 weeks and that spleen is the organ where MDV strains were the most frequently detected.

The results from this study should be reconciled with those of the dissemination studies where RN1250 was compared with another MD serotype 1 strain, Rispens strain and where it turned out that RN1250 was less frequently detected. All these results suggest that RN1250 has less replicative properties in-vivo than other MD serotype 1 strains.

Safety for various species

In study 11-036, RN1250 vaccine strain at its highest titre in the finished product (4.7 log₁₀ PFU/dose) and its highest passage (MSV+5) was administered subcutaneously to SPF chicken, quail, turkey, duck, pheasant and pigeon avian species.

Clinical signs were monitored over a 46/47-day period and MD gross lesions were investigated in dead or euthanised birds. MD seroconversion was assessed 46-47 days after vaccination.

Neither clinical signs nor lesions were found out. No birds did seroconvert to MD over this period which is not abnormal as MD serology in general is not a proper tool to monitor vaccine exposure. However, RN1250 was found to be harmless to these species directly by administration or indirectly by contact with administered birds of the same species as the wild MDV strains in the literature (Schat and Nair, 2013).

To rule out that RN1250 was able to replicate into mammalian tissues, 21 female SPF mice, 6-7 weeks old, were administered both subcutaneously and intradermally with 4.9 log₁₀ PFU in study 11-090. Five mice were investigated 3, 7 and 14 days further the administration of an overdose of the vaccine (around 10 times) by both routes. No virus was isolated from their trachea, brain, spleen, heart, liver, lungs, kidneys, and their skin tissue at the 2 sites of inoculation.

Recombination or genomic reassortment of the strains

In study 11-069, the safety of the co-administrations of RN1250 with the HVT vaccine strain or with the vMDV GA 22 was studied in 1-day old SPF chickens. RN1250 was administered above its highest recommended dose (4-4.1 log₁₀ PFU/dose) while vMDV GA22 titre was 3.7-3.6 log₁₀ PFU/dose and HVT titre was 3.9 log₁₀ PFU/dose. The body weight gain, MD associated morbidity mortality and gross lesions in sciatic nerve, liver, spleen, kidneys, gonads, bursa, and skin with feather follicles were monitored over a 35-day timespan and viraemic strain and splenic viral load was explored at day 21 and 35 respectively.

As expected, birds administered with vMDV GA 22 alone or HVT alone respectively did and didn't have MD; MD lesions were found in 15/49 vMDV GA 22 administered birds. vMDV GA 22 and HVT strains were isolated 5/5 and 8/10 spleen samples respectively 35 days after administration.

The co-administration of these strains with RN1250 decreased the course of MD caused by vMDV GA 22 while no change was reported for HVT.

In co-administration with vMDV GA 22, RN1250 decreased MD lesions upon the completion of the study (2/49 instead of 15/49 in groups RN1250+vMDV GA 22 and vMDV GA 22 respectively). However, there were no statistical differences in average body weight between the 2 groups. And only vMDV GA 22 strain was isolated and amplified in the spleen (D35) or in the blood (D21) of the co-administered chickens by a qualitative PCR.

The co-administration with HVT did not bring about any pathogenicity and again, only HVT strain was amplified in 10/10 spleens (D33) or isolated in the blood (D21).

In conclusion, when co-administered with two very different strains, a pathogenic and an apathogenic one, it was always the co-administered strain which was detected in the blood or in the spleen. However, RN1250 did have an actual effect on vMDV GA 22 by lessening its pathogenicity over the 35 days of the study. With this MDV strain, the effect was beneficial. However, the mechanisms underlying this effect are largely unknown and it is not possible to rule out the involvement of recombination.

User safety

Prevexxion RN vaccine is a cell-associated live vaccine which contains the MDV-1 recombinant strain RN1250.

In general, avian herpesviruses are not known to be a hazard to humans. Avian herpesviruses are not indicated in EU Directive 2000/54/EC on the protection of workers from risks related to exposure to biological agents at work. The genetic modifications have attenuated the genuine biological properties of the strains and a study in mice has corroborated that RN1250 does not infect mammals.

Prevexxion RN contains no adjuvant, but the following excipients: DMSO and dilution medium and is diluted in a solvent including sucrose, casein hydrolysate, phenol red 1% solution and salts before administration. The DMSO present in the vaccine is listed in Table 1 of Commission Regulation No 37/2010/EC and is considered to be safe and none of diluent's ingredients poses a risk for the user.

The vaccine is filled in glass ampoules stored in liquid nitrogen which might explode when removed from cold storage and thawed, leading to exposure or cuts by the glass. This risk is considered very low because these frozen ampoules are already very common in practice today, and users are professionals well trained to handle this kind of vaccine.

The risk of accidental self-injection of the vaccine to the user when administered subcutaneously to day-old chickens is low as the users are trained professionals and the volume to be injected is small (0.2 ml). The consequences of accidental self-administration are therefore negligible.

Pharmacovigilance for RN1250 have reported no human adverse event.

Finally, in sections 4.5 and 4.9 of the SPC the attention of the user of the vaccine is drawn on the potential risk of ampoule explosion and advices are given how to handle the administration.

Study of residues

Prevexxion RN is a vaccine which does not contain any adjuvant.

The components are either listed in table 1 of the annex of Commission Regulation No. 37/2010 as allowed substances for which no MRLs are required or considered as substances not falling within the scope of regulation (EC) No. 470/2009 (e.g. active principles of biological origin intended to produce active immunity, used in IVMPs) with regard to residues of veterinary medicinal products in foodstuffs of animal origin. The theoretical maximal concentration of gentamicin per dose of vaccine is considered negligible (≤ 3.66 ng).

Interactions

The safety of Prevexxion RN in association with Vaxxitek HVT+IBD was demonstrated in broiler and layer chickens in both laboratory and field trials. It is reported in studies 16.0388.R, 16.0201.R, 16.0202.R and 16.0200.R.

However, the compatibility claim with Vaxxitek HVT+IBD cannot be accepted during this procedure (see Interactions section in Part 4).

Field studies

Safety of the monovalent and bivalent vaccines was investigated in field studies in broilers (16.0201.R) and pullets (16.0202.R).

Study 16.0201.R was performed in order to substantiate the safety and the efficacy of the monovalent (RN1250) and bivalent (RN1250+vHVT013-69) vaccines in long-living broilers throughout their production life, until slaughter at about 80 days of age.

Vaccination with RN1250 was compared to vaccination with Cryomarex Rispens in 2 farms (4 subgroups) while vaccination with RN1250 + vHVT013-69 was compared to vaccination with Cryomarex Rispens+HVT associated with Poulvac Bursine 2 in 2 other farms (4 subgroups).

Birds were vaccinated subcutaneously at hatchery either with RN1250 or with RN1250 + vHVT013-69 at intermediate titre or with commercial batches of Cryomarex Rispens or Cryomarex Rispens+HVT. Then both vaccinated and comparator groups were raised until slaughter in 4 farms in France. Birds vaccinated with Cryomarex Rispens+HVT were vaccinated on day 20 and 26 with Poulvac Bursine 2 (Zoetis) by drinking water.

Mortality and morbidity were recorded daily as well as the feed intake. Birds randomly selected each

week were weighed. To check the vaccination take, spleen was taken from 10 birds of each subgroup at day 8/9 and blood from birds vaccinated with RN1250 + vHVT013-69 or Cryomarex Rispens+HVT/Poulvac Bursine 2 (4 subgroups) at days 29, 39, 53 and 81.

Birds were slaughtered at about 80 days of age, animals; their weight and the number of condemned animals were recorded.

Vaccine strains were detected in 90% of the spleen samples from RN1250 and RN1250 + vHVT013-69 vaccinates. Birds seroconverted to IBDV (ProfLOK Plus IBD ELISA) by 30 days after vaccination with RN1250+vHVT013-69 while 1 out of the 2 subgroups vaccinated Poulvac Bursine 2 seroconverted at day 80.

Neither immediate reactions after vaccination, nor adverse events throughout the study were reported. Mortality rate between subgroups raised in a same farm was not different and below the alert threshold of 2%.

One week after vaccination, bodyweight growth increased in RN1250 vaccinates in one farm and inversely in the other one. RN1250 + vHVT013-69 slightly increased bodyweight growth in one subgroup and didn't in the other one. However, no difference in term of slaughtered or condemned birds, feed intake and feed conversion were reported at the time of slaughter.

In conclusion, no solid differences in term of safety issues and production parameters on long-living broilers were reported between RN1250 or RN1250 + vHVT013-69 and their competitor vaccines already on the market.

The safety and efficacy on layers have been addressed in a field study (16.0202.R) where both the bivalent and monovalent vaccines were compared to Nobilis Rismavac + CA 126, an authorised vaccine with the same combination of valences or associated with Cryomarex HVT. Two different breeds of pullets (LSL Classic and Hy-Line Brown Rural) were monitored up to 30 weeks of age (12 weeks after they have started laying), each one in a multiple-site production system of 2 farms. At day 1 of age, 20,000 female chicks were injected subcutaneously with RN1250 or Nobilis Rismavac + CA 126 and about 60,000 with RN1250 + vHVT013-69 or Nobilis Rismavac + CA 126 followed by Nobilis Gumboro D78 at day 22 and 29 in the farm. From 18 weeks of age onwards, birds were transferred to 2 laying farms each farm raising a vaccine group and its control group in the same time.

The vaccine take was confirmed since the vaccine strain RN1250 was amplified by PCR overall in 67% of the spleens of the vaccinated groups sampled on day 8-9. No immediate reactions after vaccination were reported as well as no MD clinical signs, but one RN1250-vaccinated pullet showed MD paralysis 111 days after vaccination.

Overall mortality was low whatever the group and the stage of the life (1.2 to 4.2%). While mortality of birds vaccinated with RN1250+vHVT013-69 was higher than control at the pullet stage, it was the reverse at the layer stage; this observation is associated with a colibacillosis outbreak at the start of the raising. There were no differences for the group vaccinated with the monovalent vaccine.

However, no difference in body weight between vaccinates and their relative control 18 weeks after vaccination and further on, nor was the feed intake of birds reared in the same condition.

There was no difference on the quality (class 1, decommissioned and destroyed) and the number of eggs.

The applicant has provided the report of study 16.0200.R which is considered valid despite chickens were vaccinated *in ovo* with MD and IBD vaccines prior to their inclusion into this study. Regarding safety aspects, no negative impact on the outcome of the study due to prior vaccination is suggested.

Environmental risk assessment

The proposed vaccine is compliant with Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms.

The applicant has provided a detailed risk assessment of the vaccine containing RN1250 viruses compliant to NTA ENTR/F2/KK D (2006).

Hazards

The vaccine strain was shown to infect/replicate only in susceptible birds, but not in mammals and it was not isolated from feathers.

The biological pattern of the vaccine strain was shown to be not very different from its parental strain and its genetic and phenotypic stability after serial passages in chickens was acceptable. Components, other than the vaccine strains, used to formulate the vaccine are classical components, used in many biological products, known for their absence of effect on the environment.

Taking all the risk factors into consideration, the level of risk to the environment of Prevexxion RN can be considered as negligible. Prevexxion RN is not expected to pose a risk to the environment when used according to the SPC.

Environmental risk assessment for products containing or consisting of genetically modified organisms

Detailed information was provided on the possible environmental risk of the vaccine that contains one genetically modified live virus.

The vector construction, vector elements, analytical test methods and vector characteristics including genetic stability have been extensively described for the RN1250 virus strain. The vector does not contain any potentially harmful sequences. All sequences present also occur in naturally occurring viruses. The associated risk of recombination events with circulating avian retroviruses with RN1250 containing two copies of REV LTRs was thoroughly discussed and the risk assessment amended by the applicant as requested.

Information was provided on possible release of this GMO to the environment. The likelihood is considered very low. In case of spread, homologous recombination with other (wild type) herpesviruses cannot be excluded. However, such recombination events (if any) would result in viruses with the same characteristics as either the wild type variant or the vaccine virus; it cannot result in a more virulent strain. Besides birds, no other species are known to be infected with the vaccine viruses, which are non-pathogenic for humans. Consequently, there is no intrinsic risk for humans related to the vaccine.

In conclusion, the overall risk of the current vaccine towards humans and the environment could be considered negligible.

Overall conclusions on the safety documentation

The safety of the short-term clinical safety of a 10x overdose and a dose at the maximum release titre of Prevexxion RN, the association with RN1250+vHVT013-69 was investigated over 21 days further injection to 1-day-old SPF Leghorn chickens and only a slight growth retardation at the overdose occurring at the end of the study, was reported.

The long-term safety of RN1250 strain was studied at 121 days after vaccination in a Ph. Eur. 0589

compliant study and no impact on growth or MD clinical signs or lesions were observed (residual pathogenicity – 16.0013.R).

To rule out an impact of vaccination on reproductive performance, the applicant showed in a field study that RN1250 have no impact on the quantity and quality of laying in laying hens.

An absence of impact on Newcastle protection when vaccination was performed at the time when the transient lymphocyte depletion of the thymus was maximal ruled out a functional impact of Prevexxion RN vaccination on the immune system.

The biology of the RN1250 strain has been determined SPF chickens. The RN1250 strain caused a 2-week viremia in the course of which it was found in whatever organs it was searched by culture isolation or DNA amplification (lung, liver, kidney and spleen). Then the strain was only isolated in the spleen at 4 weeks and its DNA detected at 7 weeks.

By comparison with Rispens vaccine strain, which is its main parental strain, RN1250 strain exhibited a weaker biology. RN1250 was replicated in chickens less, for a shorter time and in fewer organs (and particularly not in feathers) than Rispens strain.

In feathers, RN1250 was never isolated (study 12-012) but was able to be amplified up to 2 weeks after injection (study 16.0204.R) while Rispens strain was isolated 3 weeks after injection (study 12-012 and 12-065).

No spread of RN1250 to naïve one-day-old chickens was detected in the spleen after a 7- or 6- week contact with vaccinates (studies 10-065 or 16.0204.R) in line to what was observed for the Rispens parental strain (study 10-065). However, with a more sensitive method, spread of another MDV vaccine strain (vHVT013-69) was reported for the associated application (Prevexxion RN+HVT+IBD). Therefore, an appropriate cautious warning about spreading hazard is including in the SPC.

Quail, turkey, duck, pigeon and pheasant were currently shown unsusceptible (no seroconversion, no clinical or pathological findings) to SC administration of RN1250 near its maximum titre (11-036). RN1250 was not isolated from mice after vaccination (11-090).

In 2 different reversion to virulence studies (10-130 and 15.0408.R), RN1250 load in blood increased over passages which would suggest that the viremia ability of the strain was increasing over passages. However, no MD clinical signs or gross lesions were reported in the 10 birds monitored over 49 days at each passage (10-130) nor were they reported in birds administered with a 10X overdose of MSV+2 strain or with back passage 5 strain (16.0013.R).

Recombination of the RN1250 with other Mardi viruses (MDV-1 GA22 or MDV-2 SB1) was experimentally checked in a study and their co-administration did not increase the clinical presentation which was similar to the one of the co-administered Mardi viruses suggesting that if recombination or genomic reassortment occurred, they had no detrimental impact on the safety profile of the vaccine strains. Besides the applicant has argued that wild MDV-1 naturally recombinant with avian retroviruses are circulating worldwide and that the risk of an increase of virulence further recombination with vaccine strain is highly unlikely. Therefore, recombinations, if any, are considered to pose negligible risk to the target species, the environment and the human beings.

Information concerning release of genetically modified organisms into the environment has been provided and the associated risks assessed. The GMO vaccine strain has been shown to be phenotypically stable over 5 passages. The insertion of the foreign genetic information did not change the non-pathogenic nature of the strain for the target species or other avian species or mammalians. Any risk emerging from the use of the Prevexxion RN is negligible for humans and has to be considered as low for the environment.

Since the absence of replication of the vaccine strain in mammalian tissues was corroborated by 2

experimental studies, the user safety encompasses mainly the handling of vaccine ampoules frozen in liquid nitrogen and the risks associated to needle stick injuries. An adequate warning has been included in sections 4.5 and 4.9 of the SPC.

Residues of the vaccine are not considered to represent a consumer safety concern. A withdrawal period of zero days would be appropriate.

The safety profile was confirmed in a field study with broilers and another one with pullets where the vaccine was compared to already marketed vaccines. Neither adverse reactions nor worsening of zootechnical parameters were reported.

The vaccine is considered to be safe for the target species and non-target species, the user, the consumer and the environment.

Part 4 – Efficacy

Introduction and general requirements

Efficacy of Prevexxion RN against Marek's disease was investigated. The vaccine is claimed to prevent mortality and clinical signs and reduce lesions caused by Marek's disease (MD) virus (including very virulent MD virus) after vaccination of one-day-old chicks.

Challenge model:

Studies were designed in compliance with requirements of Ph. Eur. monograph 0589 on Marek's disease vaccine (live).

MD challenge was performed with the MDV-1 strain Rb-1b which is classified as very virulent according to ADOL scale.

Efficacy parameters and tests:

The diagnostic criteria of Marek's disease applied in the laboratory studies were those described in Ph. Eur. monograph 0589, when relevant efficacy criteria set by monograph were applied.

Efficacy documentation

The efficacy of Prevexxion RN was demonstrated in 3 laboratory studies and 2 field studies associated with 2 laboratory challenges. Besides, 7 laboratory studies were added to back a compatibility claim with Vaxxitek HVT+IBD.

Trial	Injected dose in log10 PFU		Route	Type and total number of animals	Age of animals
	RN1250	vHVT013-69			
LABORATORY TESTS					
Immediate efficacy					
<i>Marek's disease</i>					
<u>11-023</u>	2.5 to 3.1	-	SC	280 SPF chicks	Day-old
<u>15.0406.R</u>	2.9	-	SC	70 SPF chicks	Day-old
Influence of maternally derived antibodies					
<i>Marek's disease</i>					
<u>16.0338.R</u>	2.9	-	SC	90 conventional pullets	Day-old
Compatibility					
<i>Marek's disease</i>					
<u>15.0406.R</u>	2.9	3.6	SC	70 SPF chicks	Day-old
<u>16.0338.R</u>	2.9	3.6	SC	90 conventional pullets	Day-old
<i>Gumboro disease</i>					
<u>16.0100.R</u>	2.9	3.6	SC	45 SPF chicks	Day-old
<u>16.0356.R</u>	3.0	3.6	SC	70 conventional broilers	Day-old
<u>17.0112.R</u>	3.0	3.6	SC	70 conventional broilers	Day-old
<u>18.0083.R</u>	3.1	3.6	SC	70 conventional broilers	Day-old
<u>17.0113.R</u>	3.0	3.6	SC	70 conventional pullets	Day-old
FIELD STUDIES					
<u>16.0201.R</u>	3.5	4.1	SC	17600 conventional broilers	Day-old
	3.6	-	SC	17600 conventional broilers	Day-old
<u>16.0202.R</u>	3.5	4.1	SC	55400 conventional pullets	Day-old
	3.6	-**	SC	20651 conventional pullets	Day-old
<i>Marek's disease</i>					
<u>17.0126.R</u>	3.5	4.1	SC	79 conventional broilers	Day-old
	3.6	-	SC	80 conventional broilers	Day-old
<u>17.0128.R</u>	3.5	4.1	SC	80 conventional pullets	Day-old
	3.6	-**	SC	80 conventional pullets	Day-old
<i>Gumboro disease</i>					
<u>17.0127.R</u>	3.5	4.1	SC	60 conventional broilers	Day-old

17.0243.R	-	-	Oral*	35 conventional broilers	Day-old
-----------	---	---	-------	--------------------------	---------

PFU: plaque forming unit; SC: subcutaneous route.

* POULVAC BURSINE 2 vaccine was tested at commercial dose and served as positive control to evaluate the vaccination program performed in the field.

** HVT FC126 at 3.5 log₁₀ PFU per bird because concomitant administration of CRYOMAREX HVT in compliance with the usual practices in layers (vaccination program regarding MD usually includes serotype 1 and serotype 3 viruses).

Laboratory trials

Dose determination

In study 11-023, the MD protection afforded by a range of doses of RN1250 monovalent vaccine, from 2.5 up to 3.1 log₁₀ PFU/dose, against a challenge with a vvMDV strain (Rb-b1) was determined 4 days after vaccination of SPF SPAFAS chickens at 1 day of age and compared to the protection provided by a SR-3 vaccine (Merial's serotype 3 MDV vaccine authorised in US). Groups of 35 birds were clinically monitored over a 45-day period.

The severity of the challenge was high; 96% of control birds were MD positive. RN1250 prevented MD in more than 80% of the chickens of all the vaccinated groups, meeting the minimum protection Ph. Eur. 0589 criteria while the SR-3 vaccine failed (protection 76%).

While RN1250 met Ph. Eur. 0589 criteria from the lowest dose of 2.5 log₁₀ PFU/dose 4 days after vaccination with a protection of 84%, the applicant chose the 3rd dose (i.e. 2.9 log₁₀ PFU) as the minimum because it provided 94% of protection.

The study can be accepted as dose determination study but not as onset of immunity study. The test vaccine was produced and tested according to the US-license. The differences to the European product are not clearly presented. Finally, the reduction of the observation period from 70 days as requested by the Ph. Eur. monograph 0589 to 45 days is not acceptable. Therefore, the onset of protection of 4 days for Marek's disease is not supported by this study.

Onset of immunity

In study 15.0406.R, the MD protection afforded by RN1250 strain only, at its minimum dose (2.9 log₁₀ PFU) or in association with vHVT013-69 at its minimum dose (3.6 log₁₀ PFU) was determined 9 days after vaccination of SPF Leghorn chicken at 1 day of age and compared to the parental RN1250 strain of the Cryomarex Rispens vaccine with the same titre. This study was compliant to Ph. Eur. 0589 and birds were monitored over 70 days.

The severity of the challenge (73% of MD positive birds) was above the threshold required by Ph. Eur. 0589.

The RN1250 at its lowest dose, alone or with vHVT013-69 prevented MD caused by a challenge with a vvMDV strain (Rb-1b) in 28/30 and 30/30 chickens which were vaccinated 9 days beforehand. This protection was comparable to the one afforded by Cryomarex Rispens (29/30).

A 9-day onset of MD immunity may thus be granted. However, 5 days could be acceptable for onset of immunity, drawn from 16.0338.R study which is more demanding than Ph. Eur. 0589 requirements.

Duration of immunity

The immunisation by herpesvirus such MDV is life long and only chicks are at risk of MDV infection. Therefore, it is accepted that no study has been undertaken to back the duration of MD immunity.

Maternally derived antibodies (MDA)

In study 16.0338.R, the protection against Marek's disease was assessed by challenge in conventional pullets (30/group) 5 days after vaccination and compared to the protection provided by Nobilis Rismavac, a vaccine with the parental Rispens strain. Pullets were vaccinated at hatching (D0) either with RN1250 alone or with RN1250+vHVT013-69 just below the minimum release dose.

MDA against MDV and IBDV were found in all the sampled birds at hatching.

The vaccination was monitored at D7 and D78. RN1250 vaccine strain was isolated in 9/10 vaccinated chickens sampled 5 days after vaccination. And antibody to IBDV was found in every RN1250 + vHVT013-69 vaccinated birds.

The IP challenge with a vvMDV strain Rb-1b 5 days after vaccination, brought about 97% of MD specific morbidity in the control group and vaccination with RN1250 and RN1250+vHVT013-69 vaccine provided a relative protection of 88% and 97% respectively. These results comply with Ph. Eur. 0589 requirements. RN1250 protection was identical to Nobilis Rismavac protection.

Although this study was performed in conventional chicken (with MDAs), an onset of immunity of 5 days for the Marek's disease protection can be accepted based on the results obtained from this study.

Interactions

Compatibility of Prevexxion RN with Vaxxitek HVT+IBD was demonstrated in several efficacy studies as well as the interference between the two vaccine strains considered.

Studies where the vaccine Prevexxion RN+HVT+IBD containing the vaccine strains from both vaccines at their proposed minimum release titre, were performed.

The efficacy of the concurrent use was demonstrated at the onset of immunity in SPF chickens (study 15.0406.R) and in conventional birds (16.0338.R).

To demonstrate protection against IBDV, several studies were provided.

The protection against Gumboro disease afforded by a Vaxxitek HVT+IBD at the minimum dose (vHVT013-69 3.6 log₁₀ PFU/dose) was determined 14 days after vaccination of SPF Leghorn chicken at 1 day of age in study 16.0100.R The adequate vaccine take was confirmed as the vaccine strain was detected by RT-PCR in 5/5 vaccinates and antibodies in 6/10 vaccinates while nothing was found in control birds. The birds were challenged with 2.8 log₁₀ EID₅₀ of a classical pathogenic strain (Faragher) by ocular route. The severity of the challenge was higher than Ph. Eur. 0587 requirement. 100% of the control chickens showed characteristic signs of the disease (5 deaths, 3 euthanised birds, microscopic lesions in the 4 surviving chickens with a score of 4 or 5).

In summary, the vaccination with 3.6 log₁₀ PFU/bird of vHVT013-69 in presence of 2.9 log₁₀ PFU/bird of RN1250 by the SC route resulted in full protection (no mortality, no clinical signs no lesions and a very higher bursa weight/body weight ratio of the vaccinates) 14 days after a challenge with a classical virulent IBD strain.

In study 16.0356.R the putative interference of maternally derived antibody with protection afforded by Vaxxitek HVT+IBD against Gumboro disease has been investigated in broilers chicks. The primary

end point was the % of birds which met Ph. Eur. 587 individual criteria. Birds had high titres of maternally derived Gumboro antibodies at hatching (4.26 +/- 0.07 ELISA titre).

Broilers were challenged 28 days after vaccination with IBDV strain 91-168/980702 while they still have Gumboro antibodies (around 3.23 +/- 0.33 ELISA titre). Unvaccinated birds did not die, nor they had Gumboro clinical signs but their bursa of Fabricius was atrophied with a histological grade of 4. One death was recorded in vaccinated group on D20 and the bird has neither previous clinical signs nor gross lesions at necropsy. The protection rate of the vaccinates which was calculated according to the Ph. Eur. individual criteria that are no notable Gumboro clinical sign and no grade 3 lesion of the bursa of Fabricius was 42%.

In study 17.0112.R the putative interference of maternally derived antibody with protection afforded by Vaxxitek HVT+IBD against Gumboro disease was investigated in conventional broilers chicks. Birds had high titres of maternally derived Gumboro antibodies at hatching (4.38 +/- 0.03 ELISA titre). Broilers were challenged days after vaccination with IBDV strain 100045/17012628 while they still have Gumboro antibodies (around 3.9 +/- 0.48 ELISA titre). Unvaccinated birds did not die, nor they had Gumboro clinical sign but their bursa of Fabricius was atrophied (bursa of Fabricius weight/body weight ration <1) with a histological grade of 4. The protection rate of the vaccinates was 65%.

In study 18.0083.R the putative interference of maternally derived antibody with protection afforded by Vaxxitek HVT+IBD against Gumboro disease has been investigated in conventional broilers chicks and compared to Cryomarex Rispens +vHVT013. Birds had high titres of maternally derived Gumboro antibodies at hatching (4.20 +/- 0.02 ELISA titre). Broilers were challenged 35 days after vaccination with IBDV strain 100045/170126 while their Gumboro MDA had merely vanished (around 3.1 +/- 0.20 ELISA titre). Unvaccinated birds did not die nor they had Gumboro clinical sign but their bursa of Fabricius was atrophied (bursa of Fabricius weight/body weight ration <1) with a histological of 3 or 4. The protection rate of the vaccinates was 100% with Prevexxion RN+HVT+IBD higher than birds vaccinated with Cryomarex Rispens +vHVT013 (80%).

In study 17.0113.R, the protection against Gumboro disease afforded Prevexxion RN by and Vaxxitek HVT+IBD at the lower dose (RN1250 strain 3.0 log₁₀ PFU/dose & vHVT 3.6 log₁₀ PFU/dose) was determined 70 days after vaccination of conventional layer chicken (ISA Brown) at 1 day of age. The conventional birds had anti-MDV antibodies (IFA) and a high level of anti-IBDV antibodies (4.34 log₁₀ ELISA titre) at vaccination (G0 control group) and anti-IBDV antibodies disappeared before challenge. The vaccine strain was detected by RT-PCR in 3/5 birds 7 days further vaccination and the anti-IBDV antibody titre of vaccinates was 4.28 log₁₀ ELISA titre 70 days after vaccination while neither vaccine strain nor anti-IBDV antibodies was found in control birds. The birds were challenged with 2.3 log₁₀ EID50/dose of a very virulent IBDV strain (100045) by ocular route. The severity of the challenge was higher than Ph. Eur. 0587 requirement. 100% of the control chickens showed characteristic signs of the disease (1 death and 20/20 chickens with a lesion score of the bursa of Fabricius of 4).

In summary, vaccination with 3.6 log₁₀ PFU/bird of vHVT in presence of 3 log₁₀ PFU/bird of RN1250 by the subcutaneous route resulted in protection (no mortality, no clinical signs no lesions of the bursa of Fabricius > 1/5 and a higher bursa weight/bodyweight ratio of the vaccinates) 70 days after a challenge with a very virulent IBDV strain.

A negative interference of RN1250 on HVT replication has been biologically characterised because the level of IBD protection decreases when RN1250/HVT ratio increased from 1:4 to 2:1 (study 19.0162.R) and the final composition have been adapted accordingly. The reverse interference does not appear to be biologically significant because both strains contribute to Marek's disease protection and while their specific contribution remains non-dissected, an analysis of this risk has concluded that this is negligible. The applicant has committed to decrease the maximum release titre of Vaxxitek HVT+IBD from 5.0 log₁₀ to 4.4 log₁₀ in order to mitigate the risk of interference identified, but the compatibility

claim for the associated use of Prevexxion RN and Vaxxitek HVT+IBD cannot be accepted in the context of the current procedure given that an amendment of the marketing authorisation of Vaxxitek HVT+IBD (decrease in the maximum release titre from 5.0 log₁₀ to 4.4 log₁₀) is required first.

Field trials

The design and the methodology of the 2 field trials have been set out in part III section C.

In trial 16.0201.R, the long-living life broilers seroconverted to IBDV (ProFLOK Plus IBD ELISA) by 30 days after their vaccination with RN1250+vHVT013-69, earlier than those vaccinated with Cryomarex Rispens+HVT which seroconverted at day 80.

Because no clinical signs suggestive of Marek's disease or Gumboro disease were anticipated to occur in the farms during the study, some birds were taken from the hatchery to be challenged in laboratory by virulent MD or IBDV strains at the onset of protection in studies 17.0126.R and 17.0127.R, respectively.

In trial 16.0202.R, 2 different breeds of pullets (LSL Classic and Hy-Line Brown Rural) were monitored up to 30 weeks of age (12 weeks after they have started laying) each one in a multiple-site production system of 2 farms. At day 1 of age, 20.000 female chicks were injected subcutaneously with RN1250 or Nobilis Rismavac + CA 126 and about 60.000 with RN1250+vHVT013-69 or Nobilis Rismavac+CA 126 followed by Nobilis Gumboro D78 at day 22 and 29 in the farm. From 18 weeks of age onwards, birds were transferred to 2 laying farms each farm raising a vaccine group and its control group in the same time. Further to the detection of a pullet with MD paralysis at 16 weeks, evidence of circulation of MDV was brought out in the dust of the building housing the RN1250+vHVT013-69 group while the CVI-988 vaccine strain was circulated in the building housing its control group. In this same farm, colibacillosis, infectious laryngotracheitis and coccidiosis were diagnosed and treated.

However, there were no conspicuous impacts on rearing parameters (body weight, egg production) and more importantly on condemned and destroyed carcasses. Thus RN1250 + vHVT013-69 did provide the same protection to circulating MDV as did Nobilis Rismavac + CA 126.

Anticipating an absence MDV or IBDV circulation, some birds were taken from the hatchery to be challenged in laboratory by virulent MDV or IBDV strains at the onset of protection studies 17.0128.R and 17.0243.R, respectively.

From study 16.0201.R, the applicant drew birds vaccinated either with RN1250 alone or with the association RN1250+vHVT013-69 to be challenged at day 5 by a very virulent MDV strain (study 17.0126.R). The study design was compliant to Ph. Eur. 0589 and long-living broilers were clinically monitored over a 70-day period

Maternally derived antibodies at hatching were found in 20/20 chickens with a mean titre of 4.37 log₁₀ ELISA titre.

The adequate take of the vaccine was confirmed since RN1250 vaccine strain was found in 5/5 and 4/5 chickens and 20/20 chickens had anti-vHVT vaccine strain antibodies at D76.

Less than 70% of the control chickens met Ph. Eur. 0589 criteria of MD infection. The applicant has justified this result by a genetic resistance of the broiler breeds (SN757K and JA657K) because the same challenge was done in study with conventional pullets and SPF layer chickens. This justification is acceptable because the genetic resistance to MDV infection and specifically broilers by comparison to laying breeds (Schat, 2008).

In the group of birds vaccinated with RN1250+vHVT013-69, 14/34 birds experienced locomotor impairment; however gross pathology and histological evidence of bacteraemia were found instead of

MD related lesions. Consequently, they were considered MD protected.

Vaccination of long-living broilers with an intermediate potency RN1250 vaccine alone or in combination with the vHVT013-69 valence provided a relative protection around 94% against a very virulent MDV strain and corroborated the 5-day onset of protection.

From study 16.0202.P, the applicant drew vaccinates either with RN1250 associated with Cryomarex HVT or with RN1250+vHVT013-69 to be challenged at day 5 with a very virulent MDV strain (study 17.0128.R). The study design was compliant to Ph. Eur. 0589 and layer chickens were clinically monitored over a 70-day period.

Maternally derived antibodies at hatching were found in 20/20 chickens with a mean titre of 4.39 log₁₀ ELISA titre.

The adequate intake of the vaccine was confirmed since RN1250 vaccine strain was found in 4/5 and 5/5 chickens and 20/20 chickens had anti-vHVT vaccine strain antibodies at D76.

In control groups 25/35 and 27/33 birds died during the monitoring period and 91% of the birds met Ph. Eur. 0589 criteria of MD infection. The challenge was thus Ph. Eur. 0589 compliant.

In the group of birds vaccinated with the RN1250+vHVT013-69, 4/31 died few days after MDV challenge; however, the isolation of an *E. coli* in one bird, gross pathology and histological evidence of bacteraemia were found instead of MD related lesions. Consequently, they were considered MD protected.

Vaccination of layer chickens with an intermediate potency RN1250 vaccine with Cryomarex HVT vaccine or in combination with vHVT013-69 valence (Prevexxion RN+HVT+IBD) provided the same relative protection of 100% against a very virulent HVT strain and corroborated the 5-day onset of protection.

In study 17.0127.R applicant drew vaccinates from study 16.0201.R and administered them with the association RN1250+vHVT013-69 to be challenged at day 29 by a very virulent IBDV strain (100045 / 170126). The study design was in accordance with Ph. Eur. 587 and long-living broilers were clinically monitored over a 10-day period.

Maternally derived antibodies at hatching were found in 20/20 chickens with a mean titre of 4.40 log₁₀ ELISA titre.

The adequate take of the vaccine was confirmed since RN1250 vaccine strain was found in 5/5 on D8.

The challenge was done 28 days after vaccination while anti-IBDV antibodies were cleared in unvaccinated group. While neither mortality nor morbidity was reported in the control group, 20/20 unvaccinated chickens were classified Gumboro positive 10 days after challenge.

Conversely, 12/20 chickens were only classified Gumboro positive that is a protection rate of 40% and the bursa of Fabricius weight/bodyweight ratio was lower in the control chickens than in the vaccinates.

Vaccination of these long-living broilers with an intermediate potency vHVT013-69 provided a protection of 40% 28 days after vaccination against a very virulent IBDV strain.

From study 16.0201.R applicant drew non-vaccinated birds which were vaccinated with Poulvac Bursine 2 vaccine as control of the severity of the IBDV challenge of study 17.0127.R (study 17.0243.R). They were administered on days 20 and 26 according to the label and the protection rate was 4%.

Overall conclusion on efficacy

The efficacy of Prevexxion RN was demonstrated in 3 laboratory studies and 2 field studies (associated with 2 laboratory challenges) and its efficacy when associated with Vaxxitek HVT+IBD in 7 additional studies.

The diagnostic criteria of Marek's disease or Gumboro disease applied in the laboratory studies were those described Ph. Eur. monograph 0589 and Ph. Eur. monograph 0587, respectively.

The MD protection was challenged by the MDV-1 strain Rb-1b which is classified as very virulent according to ADOL scale. The IBD protection, after associated used with Vaxxitek HVT+IBD, was challenged by both the classical Gumboro strain Faragher and a vvIBDV strains.

The RN1250 minimum dose of 2.9 PFU was chosen because it provided 94% of protection against a challenge with a very virulent MDV-1 strain, 4 days after vaccination (11-023). As this study was performed with the monovalent US-vaccine and the observation period after the challenge was too short, an onset of immunity for MD of 4 days is not regarded as demonstrated. A MD onset of immunity of 5 days as demonstrated in study 16.0338.R is regarded as supportable.

Maternally derived antibodies did not decrease MD protection (88% with RN1250 and 97% with RN1250+vHVT013-69) against a MD challenge at day 5 nor they did Gumboro protection when vaccinates were challenged 35 days after vaccination (100% protection rate). However, when Gumboro challenge was performed earlier when MDA were still high, the protection rate was lower (42% (16.0356.R); 40% (17.0127.R); 65% (17.0112.R)). Therefore, a negative impact on the development of protection against Gumboro disease must be expected when chickens are vaccinated in the presence of high titres of MDAs against Marek's disease. A warning has been added in section 4.8 of the SPC.

The duration of MD immunity is lifelong while IBD protection until 70 days was shown after challenge of conventional laying chickens with a very virulent IBDV strain.

In field studies which were performed in long-living broilers and in laying hens, Prevexxion RN and Prevexxion RN+HVT+IBD were compared to marketed vaccines. Broilers seroconverted earlier with the RN1250+vHVT013-69 vaccine and protection against circulating MDV similar to the comparator vaccine was reported for laying pullets. Birds from these field trials were experimentally challenged in laboratory studies.

When administered to long-living broilers, Prevexxion RN at intermediate potency alone or with associated to Vaxxitek HVT+IBD provided a relative protection around 94% against a very virulent MDV strain 5 days further vaccination and the protection was higher for layer chickens with the same study design (100%).

However, the compatibility claim for the associated use of Prevexxion RN and Vaxxitek HVT+IBD cannot be accepted in the context of the current procedure given that an amendment of the marketing authorisation of Vaxxitek HVT+IBD (decrease in the maximum release titre from 5.0 log₁₀ to 4.4 log₁₀) is required first.

Part 5 – Benefit-risk assessment

Introduction

Prevexxion RN is a vaccine containing a cell associated live GMO vaccine strain, an engineered Marek's disease virus (MDV-1) serotype 1, named RN1250 strain.

The vaccine is intended for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by Marek's disease (MD) virus (including very virulent MD virus).

The dossier was submitted in line with requirements of Article 12(3) of Directive 2001/82/EC.

Benefit assessment

Direct therapeutic benefit

In 3 laboratory and 2 field studies the vaccine was shown to be efficacious for the active immunisation of one day old chicks to prevent mortality and clinical signs and reduce lesions caused by Marek's disease (MD) virus (including very virulent MD virus).

An OOI of 5 days was established against MDV infection and no data are provided for the DOI. This is acceptable as the MD virus produces a persistent infection providing a lifelong immunity.

The OOI in conventional birds has shown that MDA could interfere with immunisation.

Additional benefits

None identified.

Risk assessment

Quality:

Information on the composition, development, manufacturing process, tests performed during manufacture and on the finished product, batch-to-batch consistency and stability of Prevexxion RN have been provided.

Safety:

Risks for the target animal:

The product is generally well tolerated in the target animal. No adverse reactions were observed after administration of Prevexxion RN.

The vaccine strain, based on a MDV1 vaccine strain in which LTR sequences from avian retroviruses were included, was shown to be safe for chickens. While no spread to contact chickens or other bird species was detected in the studies included in this dossier, an appropriate warning to separate vaccinated from non-vaccinated birds is included in the SPC because the spread may sometimes occur when the vaccinates harbours another MDV strain (wild or vaccine strain).

Risk for the user:

The user safety for this product is acceptable when used as recommended and taking into account the safety advice and also the special precautions for handling nitrogen stored products listed in the SPC and package leaflet.

Risk for the environment:

The vaccine virus is detected on the feather epithelium and the contaminated dander can persist in the environment. However, the fitness of this vaccine strain was shown lower than its parental strain which has been used in authorised vaccines for a long time. Safety studies conducted in six avian non-target species demonstrated that the vaccine strain is safe and studies in mice that it did not replicate

in mammals. Safety studies showed, that recombination (if any) would not result in more virulent strains.

The product is not expected to pose any risk to the environment when used as recommended, provided that satisfactory answers are given regarding the risk of recombination of the RN1250 strain with avian retroviruses.

Risk for the consumer:

The withdrawal period is set at zero days.

Risk management or mitigation measures

Appropriate information has been included in the SPC to inform on the potential risks of this product relevant to the target animal, user and environment and to provide advice on how to prevent or reduce these risks.

Evaluation of the benefit-risk balance

The applicant applied for the following indication: "prevention of mortality and clinical signs and reduction of lesions caused by Marek's disease (MD) virus (including very virulent MD virus)."

The product has been shown to be efficacious for these indications, and the CVMP accepted the indications as proposed by the applicant.

Information on development, manufacture and control of the active substance and finished product has been presented and lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. It is well tolerated by the target animals and presents an acceptable risk for users and the environment when used as recommended. Appropriate precautionary measures have been included in the SPC and other product information.

Based on the data presented, the overall benefit-risk is considered positive.

Conclusion on benefit-risk balance

Based on the original and complementary data presented on quality, safety and efficacy the Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the application for Prevexxion RN is approvable since these data satisfy the requirements for an authorisation set out in the legislation (Regulation (EC) No 726/2004 in conjunction with Directive 2001/82/EC).

The CVMP considers that the benefit-risk balance is positive and, therefore, recommends the granting of the marketing authorisation for the above mentioned veterinary medicinal product.